×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Challenges and Strategic Approaches to Biosimilar Development
Session Chair(s)
Jayanthi Reddy, MBA, MS
Director, Global Project Management
Merck & Co., Inc., United States
This session will focus on understanding the strategic questions companies are facing when developing biosimilars and the drug development approaches that are being adopted. Case studies will be provided followed by an open forum discussion.
Learning Objective : Describe how companies address strategic choices when evaluating new business models, using the advent of biosimilar development as a case study; Discuss different strategic approaches to biosimilar development.
Speaker(s)
CMC Challenges to Biosimilar Development
Steve Farrand, PhD, MSc
Merck Research Laboratories, United States
Vice President BioProcess Development
Clinical Challenges and Strategic Approaches to Biosimilar Development
Andrew Rankin, PhD
Pharnaceutical Consultant, United States
Pharmaceutical Consultant
Nonclinical Challenges to Biosimilar Development
Qinghai Zhao
Teva BioPharmaceuticals USA, United States
Director, Protein Sciences
Have an account?